If my CRSwNP patient is a candidate for sinus surgery, why would I consider a biologic like DUPIXENT?

Up to 87% of patients with CRSwNP have evidence of type 2 inflammation.¹¹ DUPIXENT helps address the underlying type 2 inflammation in CRSwNP by targeting two of the key drivers—IL-4 and IL-13 signaling.^1,13,14,a

^aThe mechanism of dupilumab action has not been definitively established.¹

SINUS-24 and SINUS-52

DUPIXENT is appropriate for surgery-naive or -experienced patients and may provide rapid results at Day 3 for Loss of Smell^b and Day 2 for nasal congestion,^c sustained through Week 52.^1,12,15,d-g Data in adults.^1,12,15

^bLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).^12,16 Patient-reported outcome. Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.^12,17

^cLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).^12,16 Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.¹²

^dLoS score at Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (P<0.0001).¹⁵

^eNC score at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (P<0.0001).^1,15

^fLoS score at Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.10 (95% CI: -1.31, -0.89).¹ Analysis was not multiplicity controlled. Results are descriptive.¹⁵

^gNC score at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (P<0.0001).^1,15

Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.¹

Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.¹

CRSwNP, chronic rhinosinusitis with nasal polyps; INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.

Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance treatment in adults with inadequately controlled CRSwNP.¹